Best Practices for Rectal Cancer - Summary - MDSpire
Advertisement
Best Practices for Rectal Cancer
Dana-Farber’s Young-Onset Colorectal Cancer Center's Gut Instincts series continued on Monday, September 26 with an educational workshop on Best Practices for Rectal Cancer.
To provide an overview of the latest best practices and emerging trends in the management of rectal cancer, including chemotherapy, radiation, and surgical options.
Key Findings:
Rectal cancer accounts for 30% of colorectal cancers but 40% of colorectal cancer deaths, indicating a higher mortality rate.
Tri-modality therapy is the standard for locally advanced rectal cancers.
Total neo-adjuvant therapy may improve clinical response rates and allow for organ preservation.
Interpretation:
The choice between total neo-adjuvant therapy and conventional approaches depends on specific patient factors, with the former showing promise in improving outcomes.
Limitations:
Optimal sequencing of treatments in total neo-adjuvant therapy is not yet established, which is crucial for maximizing treatment efficacy.
Current data does not demonstrate a survival benefit for total neo-adjuvant therapy compared to conventional approaches.
Conclusion:
Advancements in rectal cancer treatment are evolving, with a focus on personalized approaches to improve patient outcomes, highlighting the need for ongoing research.
Colorectal cancer (CRC) impacts about 1 in 13,000 pregnancies in the United States. This article follows the case of a 36-year-old woman diagnosed with CRC while pregnant and highlights considerations around CRC diagnosis and cancer treatment during pregnancy.
